The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.51
Bid: 3.02
Ask: 4.00
Change: 0.00 (0.00%)
Spread: 0.98 (32.45%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Dec 2016 09:28

RNS Number : 0712S
Proteome Sciences PLC
16 December 2016
 
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

PROTEOME SCIENCES PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

YES

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

VULPES LIFE SCIENCES FUND

 

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

14 DECEMBER 2016

6. Date on which issuer notified:

15 DECEMBER 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

18%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB0003104196

36,573,125

36,573,125

52,973,125

52,973,125

18.00%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

52,973,125

18.00%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

executive.pa@proteomics.com 

 

14. Contact name:

Victoria Birse

15. Contact telephone number:

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

VULPES LIFE SCIENCES FUND

Contact address

(registered office for legal entities)

 

c/o Maples Corporate Services Limited, PO

Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands

Phone number & email

 

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Stephen Diggle

Contact address

 

One George Street #07-03 Singapore 049145

 

Phone number & email

 

Tel: (65) 6538 1998 (Main)

Email: sdiggle@vulpesinvest.com

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

Director

C: Additional information

Email address: Complete the required TR-1 form and email it to: Major shareholdings majorshareholdings@fca.gov.uk Fax number: You can print the TR-1 form, complete it and fax it to: 020 7066 0050

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGGAPPUPQUBQ
Date   Source Headline
14th Jul 20117:00 amRNSCollaboration with Buck Institute - biomarket test
7th Jul 20117:00 amRNSCollaboration Agreement
29th Jun 20111:31 pmRNSAGM Statement
28th Jun 20118:12 amRNSDenamic ?6.9m EU Framework Grant
6th Jun 20111:21 pmRNSAnnual Financial Report
27th May 20117:00 amRNSFinal Results
27th May 20117:00 amRNSFinal Results
29th Mar 20117:00 amRNSTakeda Research Contract
28th Mar 20114:38 pmRNSBlocklisting Interim Review
8th Mar 20114:40 pmRNSSecond Price Monitoring Extn
8th Mar 20114:35 pmRNSPrice Monitoring Extension
31st Jan 20117:00 amRNSContract for Biomarker Services with Eisai
10th Jan 20113:39 pmRNSDirector/PDMR Shareholding
23rd Dec 20107:00 amRNSDirectorate Change
20th Dec 20107:00 amRNSResearch Contract
30th Nov 20107:00 amRNSTrading Statement
23rd Nov 201010:30 amRNSBlocklisting Interim Review
23rd Nov 20109:46 amRNSHolding(s) in Company
15th Nov 20107:00 amRNSProteome Sciences form alliance with ICON
14th Oct 20103:00 pmRNSHolding(s) in Company
30th Sep 20107:00 amRNSHalf Yearly Report
28th Sep 20107:00 amRNSStatement re Warranty Claim
23rd Sep 20107:00 amRNSCollaboration with Thermo Fisher
21st Jul 20104:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSProduct Launch
6th Jul 20101:11 pmRNSDirector/PDMR Shareholding
1st Jul 201011:10 amRNSHolding(s) in Company
30th Jun 20104:27 pmRNSResult of AGM,Loan Conversion,Total Voting Rights
28th Jun 20105:59 pmRNSCOMPLETION OF PLACING AND OVERSUBSCRIBED OPEN OFFE
18th Jun 20107:00 amRNSUpdate on warranty claim
17th Jun 20109:00 amRNSReport and Accounts
11th Jun 20107:00 amRNSPublication of Circular
8th Jun 201011:21 amRNSHolding(s) in Company
7th Jun 20104:40 pmRNSSecond Price Monitoring Extn
7th Jun 20104:35 pmRNSPrice Monitoring Extension
7th Jun 20104:22 pmRNSPreliminary Results
7th Jun 20104:17 pmRNSPlacing, Open Offer & Loan Conversion
2nd Jun 20107:00 amRNSReimbursement of lung cancer test in USA
26th Apr 201011:55 amRNSBlocklisting Interim Review
9th Apr 20107:00 amRNSLicense Agreement
11th Feb 20108:18 amRNSAlliance with Parexel
9th Feb 20107:00 amRNSChange of Adviser
1st Feb 20102:01 pmRNSHolding(s) in Company
23rd Dec 20093:55 pmRNSDirectorate Change
16th Nov 20091:39 pmRNSHolding(s) in Company
28th Oct 20097:00 amRNSRe Contract
26th Oct 20097:00 amRNSBlock Admission
23rd Oct 20094:40 pmRNSSecond Price Monitoring Extn
23rd Oct 20094:35 pmRNSPrice Monitoring Extension
30th Sep 20097:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.